v2.4.0.6
CONDENSED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2011
Dec. 31, 2010
CURRENT ASSETS:    
Cash and cash equivalents $ 89,526 $ 40,030
Short-term investments 3,735 23,351
Prepaid expenses and other current assets 728 1,865
Total current assets 93,989 65,246
Property and equipment - net 1,316 17
Debt issuance costs 275  
TOTAL 95,580 65,263
CURRENT LIABILITIES:    
Accounts payable 17,476 3,791
Accrued clinical studies 5,131 3,137
Accrued liabilities 401 468
Accrued payroll and related costs 781 609
Total current liabilities 23,789 8,005
Notes payable - net of discount 24,128  
Total liabilities 47,917 8,005
Commitments and Contingencies (Note 6)      
Stockholders' equity    
Preferred stock, $0.001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2011 and December 31, 2010      
Common stock, $0.001 par value, 95,000,000 shares authorized; 40,899,668 and 32,853,032 shares issued and outstanding as of September 30, 2011 and December 31, 2010, respectively 41 33
Additional paid-in capital 219,491 162,919
Accumulated comprehensive loss (46) (50)
Deficit accumulated during the development stage (171,823) (105,644)
Total stockholders' equity 47,663 57,258
TOTAL $ 95,580 $ 65,263